Wilmington, DE -- (SBWIRE) -- 10/22/2013 -- Equity Profile Report expands its NASDAQ Active Stock Weekly Watch List adding DURECT Corporation (NASDAQ:DRRX) and Oncolytics Biotech Inc. (NASDAQ:ONCY).
DURECT Corporation (NASDAQ:DRRX) a specialty pharmaceutical company that develops pharmaceutical systems technologies based on its proprietary drug delivery technology platforms is currently up (+9.29%) on 4,127,966 shares traded after DURECT CORP Filed SEC form 8-K, Other Events, Financial Statements and Exhibits. DURECT Corporation (NASDAQ:DRRX) is currently up (+155.74%) from its recent 52-week low which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List.
Click Here to find out what other Investors are saying about DURECT Corporation (NASDAQ:DRRX)
Oncolytics Biotech Inc. (NASDAQ:ONCY) a development stage biopharmaceutical company that focuses on the discovery and development of pharmaceutical products for the treatment of cancers is currently down (-1.07%) on 300,728 shares traded after Oncolytics Biotech Inc. Announced Progression Free Survival Data for Phase 2 Study of REOLYSIN in Squamous Cell Lung Cancer. Oncolytics Biotech Inc. (NASDAQ:ONCY) is currently down (-41.99%) from its recent 52-week high which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List.
Click Here to find out what other Investors are saying about Oncolytics Biotech Inc. (NASDAQ:ONCY)
Equityprofilereport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities.
Through a vast network of IR professionals Equityprofilereport.com is often aware of several large investor awareness campaigns being deployed.
Timing is important when trading Small Caps and Penny Stocks.
Simply sign up for free and start receiving exclusive alerts.
Subscribe Here: http://www.Equityprofilereport.com
Disclosure: Equityprofilereport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit Equityprofilereport.com website, for complete risks and disclosures.
Equity Profile Report
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)